comparison of concomitant mesalamine and immunomodulator therapy and immunomodulator monotherapy for crohn’s disease
Clicks: 200
ID: 155582
2018
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
200 views
24 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #73 of 188 articles by views in colloids and surfaces a: physicochemical and engineering aspects
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 188 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Background. Although immunomodulators are increasingly used in Crohn’s disease (CD), a significant number of gastroenterologists still use 5-aminosalicylate (5-ASA) in combination with azathioprine (AZA) or 6-mercaptopurine (6-MP); there is limited evidence regarding the benefit of concomitant 5-ASA with AZA/6-MP compared with AZA/6-MP monotherapy for the treatment of CD. Study Design. A total of 106 patients who received AZA/6-MP for more than 3 months between January 1991 and May 2014 were identified retrospectively. Each patient was matched with 3 randomly selected controls who were treated with concomitant therapy during the same period. Results. The cumulative probabilities of steroid use at 5 and 10 years were 24.9% and 75.8% in the 5-ASA + AZA/6-MP group and 31.2% and 87.8% in the AZA/6-MP group, respectively (P=0.187). The cumulative probabilities of anti-TNF use, resectional surgery, and disease-related hospitalization were comparable between the groups. The younger age and the use of lower doses of immunomodulators were associated with higher requirement of rescue therapy. Conclusions. This study did not demonstrate that the concomitant use of 5-ASA with AZA/6-MP showed the proof or effect in terms of steroid requirements, anti-TNF use, resectional surgery, or disease-related hospitalization compared with that of AZA/6-MP alone.
| Reference Key |
kwak2018gastroenterologycomparison
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Min Seob Kwak;Kyung-Jo Kim;Jae Hee Cheon;Wan Soo Kim;Jeong-Mi Lee;Sung Wook Hwang;Sang Hyoung Park;Dong-Hoon Yang;Byong Duk Ye;Jeong-Sik Byeon;Seung-Jae Myung;Suk-Kyun Yang |
| Journal | colloids and surfaces a: physicochemical and engineering aspects |
| Year | 2018 |
| DOI |
10.1155/2018/4826973
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.